Dr. Soileau discusses the clinical role of continuous subcutaneous Vyalev (foscarbidopa/foslevodopa) therapy for patients with Parkinson’s disease experiencing motor fluctuations despite optimized oral treatment. He reviews clinical trial data demonstrating increased “on” time without troublesome dyskinesia and explains how continuous subcutaneous delivery bypasses gastrointestinal absorption challenges to provide more consistent levodopa exposure throughout the day and night. Dr. Soileau also highlights practical advantages of the therapy, including improved management of nighttime and early morning symptoms, reduced fluctuations associated with oral dosing, and the ability to precisely titrate levodopa doses for individualized patient care.
